Wednesday, October 22, 2025

Revive Therapeutics Conducts $10.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this evening announced that it will be conducting a bought deal financing, lead by Leede Jones Gable and Canaccord Genuity Corp. The financing will see the company raise $10.0 million through the sale of units at a price of $0.50 per each.

A total of 20.0 million units are expected to be sold under the financing, with each unit consisting of one common share and one common share purchase warrant. Each warrant is valid for a period of three years from the date of issuance, and contains an exercise price of $0.70 per share.

An acceleration clause is also present on the warrants, enabling the company to accelerate the expiry of the warrants if the equity trades above $1.10 for a period of ten consecutive trading days on a volume weighted basis. A 15% over-allotment option has also been granted to the underwriters, valid for a period of 30 days from the closing of the financing.

Net proceeds from the financing are to be used for phase 3 clinical costs for the use of Bucillamine in the treatment of COVID-19, phase 1 clinical costs for psilocybin for methamphetamine use disorder study, as well as other psychedelic formulation development work, working capital, and general corporate purposes.

Revive Therapeutics last traded at $0.60 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Steadright Enters MOU To Acquire Historic Goundafa Polymetallic Mine In Morocco

Military Seizes Power in Madagascar After President Flees

Related News

Revive Sees Expanded Access Protocol Approved For Compassionate Use Of Bucillamine

Revive Therapeutics (CSE: RVV) this morning announced that it has received approval from the Independent...

Wednesday, September 16, 2020, 08:23:03 AM

Revive Therapeutics Enters Exclusive License For Ganoderma Lucidum Intellectual Property

Revive Therapeutics (CSE: RVV) last night announced that it has has entered into an exclusive...

Wednesday, August 18, 2021, 09:23:10 AM

Revive Therapeutics Adds Turkish Subjects To Bucillamine Phase 3 Clinical Trial For COVID-19

Revive Therapeutics (CSE: RVV) announced on Wednesday that it has expanded its phase 3 clinical...

Thursday, December 30, 2021, 12:49:00 PM

Revive Therapeutics To Expand Clinical Sites For Covid-19 Related Phase 3 Study

Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase...

Friday, February 26, 2021, 08:54:19 AM

Revive Therapeutics Selects Novotech As APAC Contract Research Organization

Revive Therapeutics (CSE: RVV) this morning has continued its push towards studying Bucillamine as a...

Wednesday, April 8, 2020, 09:37:45 AM